Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Oasmia Pharmaceutical AB (NASDAQ: OASM) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Oasmia Pharmaceutical AB (NASDAQ: OASM) concerning whether a series of statements by Oasmia Pharmaceutical AB regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 9, 2019, the Company revealed that it had ended its “engagement and cooperation” with former executive chairman Julian Aleksov after a tax audit revealed missing funds related to suspicious transactions between Oasmia and companies controlled by Aleksov and his father-in-law.

Following this news, NASDAQ: OASM fell $0.34 per share, or nearly 13%, to close at $2.26 per share on July 10, 2019.

Based in Uppsala, Sweden, and founded in 1988 Oasmia Pharmaceutical AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden.

If you purchased shares of Oasmia Pharmaceutical AB (NASDAQ: OASM) on or before July 9, 2019, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185